Management and treatment of herb-induced liver injury

Xin SUN; Qiong LUO; Tao YANG; Chenghai. LIU

doi:10.12449/JCH240806

Volume 40 Issue 8

Aug. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(8): 1538-1542

PDF( 663 KB)

Management and treatment of herb-induced liver injury

DOI: 10.12449/JCH240806

Xin SUN^{1a, 2},
Qiong LUO^1a,
Tao YANG^{1b, 2},
Chenghai. LIU^{1a, 2, 3
,
,
,}

1a.
Institute of Liver Diseases，Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine，Shanghai 201203，China
1b.
Institute of Cardiovascular Disease，Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine，Shanghai 201203，China
2.
Shanghai Key Laboratory of Traditional Chinese Clinical Medicine，Shanghai 201203，China
3.
Key Laboratory of Liver and Kidney Diseases，Ministry of Education，Shanghai 201203，China

Research funding:

High-level Key Discipline Construction Project from State Administration of Traditional Chinese Medicine of China (zyyzdxk-2023060);

Shanghai TCM Development Three-Year Action Plan Project (ZY（2018-2020）-CCCX-5001);

Shanghai Science and Technology Innovation Action Plan Medical Innovation Research Special Project (20Z21900100);

Shanghai Key Specialty of Traditional Chinese Clinical Medicine (shslczdzk01201)

Received Date: 2024-06-15
Accepted Date: 2024-07-05
Published Date: 2024-08-25

Abstract

Abstract

Due to the diverse application forms of Chinese herbal medicine products， the wide range of users， and the complex conditions of medication in China， adverse events including herb-induced liver injury （HILI） occur frequently in recent years. In order to further understand HILI and standardize its risk management and prevention and treatment measures， this article discusses the risk management， clinical evaluation， prevention， and treatment of HILI based on related clinical research advances and experience in recent years. In the multiple links of traditional Chinese medicine including production and clinical application after marketing， the establishment of a comprehensive control system is of great importance for the prevention and treatment of HILI and other adverse events， involving product quality control， patient safety education， rational drug use by clinicians， regular monitoring， and graded and classified treatment， which provides a reference for the rational and safe clinical use of Chinese herbal medicine in the future.
- Drugs， Chinese Herbal,
- Chemical and Drug Induced Liver Injury,
- Therapeutics

FullText(HTML)

References(20)

References

[1]	Center for Drug Evaluation, National Medicine Products Administration. Guidelines for identification, management, and assessment of drug-induced liver injury in clinical trials[J]. J Clin Hepatol, 2023, 39( 8): 1811- 1816. DOI: 10.3969/j.issn.1001-5256.2023.08.007. 国家药品监督管理局药品审评中心. 临床试验中的药物性肝损伤识别、处理及评价指导原则[J]. 临床肝胆病杂志, 2023, 39( 8): 1811- 1816. DOI: 10.3969/j.issn.1001-5256.2023.08.007.
[2]	LI M, LI RR, LIU CH. Clinic diagnosis and treatment of herb-induced liver injury[J]. Chin J Pharmacovigil, 2023, 20( 2): 127- 131. DOI: 10.19803/j.1672-8629.20220661. 李盟, 李容容, 刘成海. 中草药引起肝损伤的临床诊治与用药[J]. 中国药物警戒, 2023, 20( 2): 127- 131. DOI: 10.19803/j.1672-8629.20220661.
[3]	Committee on DILI Prevention and Management, Chinese Medical Biotechnology Association; Study Group of Drug-Induced Liver Disease, Chinese Medical Association for the Study of Liver Diseases. Chinese guideline for diagnosis and management of drug-induced liver injury(2023 version)[J]. Chin J Gastroenterol, 2023, 28( 7): 397- 431. DOI: 10.3760/cma.j.cn501113-20230419-00176. 中国医药生物技术协会药物性肝损伤防治技术专业委员会, 中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南(2023年版)[J]. 胃肠病学, 2023, 28( 7): 397- 431. DOI: 10.3760/cma.j.cn501113-20230419-00176.
[4]	World Health Organization. Key technical issues of herbal medicines with reference to interaction with other medicines[M]. Geneva: World Health Organization, 2021.
[5]	FONTANA RJ, LIOU I, REUBEN A, et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury[J]. Hepatology, 2023, 77( 3): 1036- 1065. DOI: 10.1002/hep.32689.
[6]	LIU YJ, RAN S, CHEN ZD, et al. Exploration of the standardized reporting procedure for drug-induced liver injury related to Chinese materia medica[J]. J Beijing Univ Tradit Chin Med, 2023, 46( 11): 1582- 1586. DOI: 10-3969/j.issn.1006-2157.2023.11.013. 刘玉娟, 冉姗, 陈志东, 等. 关于中药相关药物性肝损伤的规范化报告程序的探讨[J]. 北京中医药大学学报, 2023, 46( 11): 1582- 1586. DOI: 10-3969/j.issn.1006-2157.2023.11.013.
[7]	Chinese Society for Tuberculosis, Chinese Medical Association. Guidelines for the diagnosis and treatment of antituberculous drug-induced liver injury(2019 edition)[J]. Chin J Tuberc Respir Dis, 2019, 42( 5): 343- 356. DOI: 10.3760/cma.j.issn.1001-0939.2019.05.007. 中华医学会结核病学分会. 抗结核药物性肝损伤诊治指南(2019年版)[J]. 中华结核和呼吸杂志, 2019, 42( 5): 343- 356. DOI: 10.3760/cma.j.issn.1001-0939.2019.05.007.
[8]	LIU SY, LI M, TANG Y, et al. Research progress on the mechanism of liver injury by polygonum multiflorum and attenuation and synergism[J]. Cent South Pharm, 2024, 22( 4): 1008- 1015. DOI: 10.7539/j.issn.1672-2981.2024.04.028. 刘思雨, 李敏, 唐瑜, 等. 何首乌肝损伤机制及减毒方法研究进展[J]. 中南药学, 2024, 22( 4): 1008- 1015. DOI: 10.7539/j.issn.1672-2981.2024.04.028.
[9]	HE N, MA ZZ, WANG QY, et al. Euodiae Fructus(Wuzhuyu): Exploring traditional Chinese medicine compatibility for reducing toxicity[J]. Chin Tradit Herb Drugs, 2024, 55( 6): 1812- 1838. DOI: 10.7501/j.issn.0253-2670.2024.06.005. 何宁, 马珍珍, 王秋月, 等. 有毒中药吴茱萸及减毒配伍研究探讨[J]. 中草药, 2024, 55( 6): 1812- 1838. DOI: 10.7501/j.issn.0253-2670.2024.06.005.
[10]	ZHANG Y, WANG XY, DING ZH, et al. Systematic review on safety of Chinese medicines combined with Tripterygium wilfordii preparations in treatment of rheumatoid arthritis and exploration on underlying network regulatory mechanisms of enhancing efficacy and reducing toxicity[J]. Chin J Exp Tradit Med Formulae, 2023, 29( 5): 1- 8. DOI: 10.13422/j.cnki.syfjx.20220943. 张依, 王晓月, 丁子禾, 等. 中药配伍雷公藤制剂治疗类风湿关节炎的安全性系统评价及其增效减毒网络调控机制[J]. 中国实验方剂学杂志, 2023, 29( 5): 1- 8. DOI: 10.13422/j.cnki.syfjx.20220943.
[11]	LIU Q, GUO YL, DONG TW, et al. Research progress on hepatotoxicity mechanism and attenuation methods of psoraleae fructus[J]. Chin J Exp Tradit Med Formulae, 2021, 27( 11): 233- 239. DOI: 10.13422/j.cnki.syfjx.20210626. 刘巧, 郭延丽, 董泰玮, 等. 补骨脂肝损伤机制及减毒方法研究进展[J]. 中国实验方剂学杂志, 2021, 27( 11): 233- 239. DOI: 10.13422/j.cnki.syfjx.20210626.
[12]	GE XX, ZHANG PP, WU Q, et al. Study on the toxic reduction and mechanism of Huangyaozi compatibility based on liver injury[J]. Mod Chin Med, 2023, 43( 3): 1- 5. DOI: 10.13424/j.cnki.mtcm.2023.03.001. 葛肖肖, 张盼盼, 仵琼, 等. 基于肝损伤的黄药子配伍减毒及其作用机制研究[J]. 现代中医药, 2023, 43( 3): 1- 5. DOI: 10.13424/j.cnki.mtcm.2023.03.001.
[13]	WANG T, SUN K, LI JY, et al. Study of triptolide on liver injury and detoxification strategy[J]. Chin J Exp Tradit Med Formulae, 2024, 30( 6): 196- 204. DOI: 10.13422/j.cnki.syfjx.20231126. 王婷, 孙珂, 李静颐, 等. 雷公藤甲素的肝损伤及减毒策略[J]. 中国实验方剂学杂志, 2024, 30( 6): 196- 204. DOI: 10.13422/j.cnki.syfjx.20231126.
[14]	CAO YJ. The study of molecular mechanism for liver injury induced by epimedium based on metabolomics and network toxicology[D]. Beijing: Beijing University of Chinese Medicine, 2021. 曹一佳. 基于代谢组学和网络毒理学初步探究淫羊藿引发肝损伤的分子机制[D]. 北京: 北京中医药大学, 2021.
[15]	WANG G, ZHANG D, CHEN X. Prophylactic treatment with Hugan Tablets for antituberculosis drug-induced liver injury: A systematic review and meta-analysis of randomized controlled trials[J]. Chin J Integr Tradit West Med Liver Dis, 2024, 34( 1): 42- 48. DOI: 10.3969/j.issn.1005-0264.2024.001.009. 王岗, 张丹, 陈新. 护肝片预防性治疗抗结核药物性肝损伤的Meta分析[J]. 中西医结合肝病杂志, 2024, 34( 1): 42- 48. DOI: 10.3969/j.issn.1005-0264.2024.001.009.
[16]	CHALASANI NP, HAYASHI PH, BONKOVSKY HL, et al. ACG Clinical Guideline: The diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol, 2014, 109( 7): 950- 966;quiz967. DOI: 10.1038/ajg.2014.131.
[17]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury[J]. J Hepatol, 2019, 70( 6): 1222- 1261. DOI: 10.1016/j.jhep.2019.02.014.
[18]	U.S. Department of Health and Human Service Food and Drug Administration, Center for Drug Evaluation and Research(CDER), Center for Biologics Evaluation and Research(CBER). Guidance for Industry: Drug-induced Liver Injury: Premarketing Clinical Evaluation[R/OL].( 2009-07). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-induced-liver-injury-premarketing-clinical-evaluation. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-induced-liver-injury-premarketing-clinical-evaluation
[19]	Branch of Hepatobiliary Diseases, China Association of Chinese Medicine, Branch of Chinese Patent Medicine, China Association of Chinese Medicine. Guideline for diagnosis and treatment of herb-induced liver injury[J]. J Clin Hepatol, 2016, 32( 5): 835- 843. DOI: 10.3969/j.issn.1001-5256.2016.05.003. 中华中医药学会肝胆病分会, 中华中医药学会中成药分会. 中草药相关肝损伤临床诊疗指南[J]. 临床肝胆病杂志, 2016, 32( 5): 835- 843. DOI: 10.3969/j.issn.1001-5256.2016.05.003.
[20]	LI M, LUO Q, TAO YY, et al. Pharmacotherapies for drug-induced liver injury: A current literature review[J]. Front Pharmacol, 2021, 12: 806249. DOI: 10.3389/fphar.2021.806249.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (283) PDF downloads(89)

Management and treatment of herb-induced liver injury

DOI: 10.12449/JCH240806

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Management and treatment of herb-induced liver injury

DOI: 10.12449/JCH240806

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content